Thermal ecology of Plesiopelma longisternale: novel insights and comparative analysis with a sympatric species

Posted by
  Thermal ecology of Plesiopelma longisternale: novel insights and comparative analysis with a sympatric species Abstract Understanding thermal responses in ectotherms is key to assessing vulnerability to climate change. Tarantulas (Theraphosidae) are informative models due to their sedentary lifestyle, long life cycles, and reliance on specific microhabitats. We present the first integrative assessment of the thermal ecology of Plesiopelma longisternale , a widespread Argentine species, combining experimentally derived thermal limits and thermal preferences with species distribution models, and compare its thermal profile with the sympatric Grammostola vachoni to explore patterns of thermal niche differentiation. Plesiopelma longisternale showed a minimum thermal limit near 4 °C, a maximum near 44 °C, a thermal optimum of 29.5 °C, a narrow thermal performance breadth, and a preferred temperature of approximately 32 °C. Models integrating climatic and thermal parameters predicted...

In vitro inhibition of snake venom toxins by varespladib, marimastat, nafamostat and dimercaprol

Posted by

 

By Holger Krisp - Own work, CC BY 3.0, https://commons.wikimedia.org/w/index.php?curid=17574465

In vitro inhibition of snake venom toxins by varespladib, marimastat, nafamostat and dimercaprol

Abstract

Snakebite envenoming causes more than 130,000 deaths and more than 400,000 disabilities per year and has been classified as a priority Neglected Tropical Disease by the World Health Organization (WHO). While antivenom therapy remains the mainstay of snakebite treatment, small molecule therapeutics (SMTs) have been proposed as potential adjuncts to antivenom, particularly as oral treatment in the prehospital setting. Several SMTs have demonstrated efficacy in preclinical models of snakebite envenoming, with varespladib, a secreted phospholipase A2 (sPLA2) inhibitor, being granted orphan drug status for its potential to treat snakebite. The present study investigated the potential of four SMTs (e.g., varespladib, marimastat, nafamostat and dimercaprol) to neutralise toxic components present in the venom of southern African snake species. In vitro experimentation found that varespladib potently inhibited snake venom phospholipase A2 (svPLA2) activity in Bitis arietans (IC50 = 0.221 μM) and B. gabonica (IC50 = 0.276 μM). Marimastat exhibited potent inhibition of snake venom metalloproteinase (svMP) in several snake species with IC50 values ranging from 0.0042–3.06 μM, while dimercaprol, a metal chelator, was a lower potency svMP inhibitor with IC50 values ranging from 5.01–79.8 μM. Nafamostat proved to be an inhibitor of snake venom serine protease (svSP) in B. arietans (IC50 = 3.72 μM), B. gabonica (IC50 = 3.80 μM) and Causus rhombeatus (IC50 = 0.261 μM). These data demonstrate that SMTs are effective inhibitors of the relevant enzymes in several snake species and support the proposal that SMTs could be developed for therapeutic intervention in snakebite envenoming.
Le Roux, A., Cloete, S. J., Petzer, J. P., & Petzer, A. (2025). In vitro inhibition of snake venom toxins by varespladib, marimastat, nafamostat and dimercaprol. Toxicon, 108626. https://doi.org/10.1016/j.toxicon.2025.108626